Translocation renal cell carcinoma is a newly recognized subtype of renal cell carcinoma (RCC) with chromosomal translocations involving TFE3 (Xp11.2) or, less frequently, TFEB (6p21). Xp11 translocation RCC was originally described as a pediatric neoplasm representing 20% to 40% of pediatric RCCs, with a much lower frequency in the adult population. TFEB translocation RCC is very rare, with approximately 10 cases reported in the literature. Here, we describe the clinicopathologic features of adult translocation RCC from a single institution. Using tissue microarray, immunohistochemistry, cytogenetic examination, and fluorescence in situ hybridization, we identified 6 (B5%) cases of TFE3 translocation RCC and 1 ( < 1%) case of TFEB translocation RCC in 121 consecutive adult RCC cases between 2001 and 2009. Our results suggest that weak TFE3 staining of a significant proportion of RCC cases may be because of expression of the full-length TFE3 protein rather than the chimeric fusion protein resulting from chromosomal translocation.
R enal cell carcinomas (RCCs) are a heterogenous group of tumors that account for approximately 90% of all adult renal malignancies. The most common subtypes are clear cell (60% to 75%), papillary (10% to 15%), chromophobe (5%), and collecting duct carcinoma, each with unique associated features at the molecular and genetic levels. Recent progress in the understanding of molecular alterations defining kidney tumorigenesis has led to the development of a new array of ancillary studies, providing a better approach to the subclassification of these tumors. 28, 29 Xp11 translocation renal cell carcinomas have been recently recognized as a distinct subset of renal carcinomas associated with a number of gene rearrangements involving the TFE3 gene on chromosome Xp11.2. The gene rearrangements result in the overexpression of several fusion proteins that contain the C-terminal portion of TFE3, a member of the microphthalmia-associated transcriptional factor family (MITF). At least 5 known fusion gene partners, including ASPL on 17q25, 2,24 PRCC on 1q21, 32 PSF on 1q34, 17 NonO on Xq12, 17 and CLTC on 17q23, 10 have been reported to date. Furthermore, t(X;3) (p11;q23) 11, 34 and t(X;19)(p11.2;q13.1) 13 have also been reported without a defined gene partner. A closely related but rare variant of RCC harboring the t(6;11)(p21; q12) 8, 19 translocation involves the transcription factor EB (TFEB), also a member of the MITF family. The Alpha-TFEB fusion in TFEB translocation RCC results in dysregulated expression of the full-length TFEB protein. 8, 19 It has been demonstrated that nuclear labeling for TFE3 and TFEB is a sensitive and specific diagnostic marker for tumors with TFE3 9 and TFEB 8 translocation RCCs, respectively.
MiTF, TFE3, TFEB, and TFEC belong to the same microphthalmia transcription factor (MiTF) family. 30 Members of the MiTF family form homodimers and heterodimers in all combinations to bind similar or identical DNA sequences of similar downstream target genes. 30 Because TFE3 and TFEB translocation RCCs share clinical, histopathologic, immunohistochemical, and molecular features, Argani and Ladanyi proposed to regroup these neoplasms under the category of "MiTF/TFE translocation carcinoma family." 6 The frequency of adult TFE3 translocation carcinoma has been reported to be about 1% 14 to 1.6% 25 of all renal tumors; however, its actual incidence remains largely underestimated. In the present study, we examined all adult RCCs diagnosed at our institution between 2001 and 2009 using tissue microarray (TMA), immunohistochemistry (IHC), cytogenetics, and fluorescence in situ hybridization (FISH), a combined tissue-based and molecular diagnostic algorithmic approach that has never been carried out before. Six cases of TFE3 translocation RCCs and 1 case of TFEB translocation RCC were identified, and their clinical and histopathologic features are reviewed here. In addition, RCCs presenting with weak nuclear TFE3 staining were investigated in-depth.
MATERIALS AND METHODS

Tissue Samples and TMA Construction
After Institutional Review Board approval (protocol #0120080157), a total of 121 consecutive cases (from 2001 to 2009) with a diagnosis of RCC were obtained from files of the Pathology Department of the New Jersey Medical School, University Hospital, Newark. In all cases, tissues were fixed in neutral-buffered formalin and embedded in a paraffin block as part of a routine surgical pathology procedure.
For TMA construction, 3 cores (1.0 mm in diameter) of each tumor from patient paraffin blocks were paired with 1 core from non-neoplastic kidney taken from donor paraffin blocks. The final TMAs consisted of up to 280 tissue cores per slide with a 1.5 mm space between each core. After construction, 4-mm sections were cut, and H&E staining was performed on the initial slide to verify the histology.
IHC
After initial deparaffinization, endogenous peroxidase activity was blocked with 0.3% H 2 O 2 . Deparaffinized sections were microwaved in 10 mmol/L citrate buffer (pH 6.0). The slides were then incubated for 1 hour at room temperature using goat polyclonal anti-human TFE3 (1:300; Santa Cruz sc-5958) or TFEB (1:400; Santa Cruz sc-11004), followed by biotinylated rabbit anti-goat IgG (Vector Laboratories, Burlingame, CA) for 30 minutes, and finally with an ABComplex (Vector Laboratories). 3 The bound complex was visualized with 0.125% amino-ethyl carbazole (AEC, Sigma, St Louis, MO) and 0.003% (vol/vol) H 2 O 2 . The sections were then counterstained in Mayer's hematoxylin. For negative controls, the primary antibody was replaced with phosphate-buffered saline.
TFE3 Gene Rearrangement Assessment by FISH
A dual-color, break-apart FISH assay for TFE3 gene rearrangement was performed on the formalin-fixed paraffin-embedded TMA slides as described earlier. The normal result is a colocalization of red and green signals, whereas a TFE3 rearrangement results in a split signal.
Cytogenetic Analysis
A fresh sample of tumor was collected in RPMI tissue culture medium and was sent directly to the cytogenetics laboratory. The tumor tissue was carefully sliced into small pieces and further treated with collagenase (3 mg/mL of Hank's balanced salt solution, Roche/ Boehringer, IN) for 2 hours to yield the highest possible concentration of cells. These cells were cultured in RPMI 1640 solution for 3 to 5 days on a coverslip dish (MatTek Corp., Ashland, MA). After adding 10 mL of colchicine (10 mg/mL of Hank's balanced salt solution) to each chamber for 45 minutes, the cells were harvested. The slides were prepared using standard in situ techniques. The chromosomes on the slides were G-banded after trypsin pretreatment. The aberrations were designated according to the International System for Human Cytogenetic Nomenclature (1995).
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
RNA extraction was performed on a frozen tissue using a standard organic extraction method (Trizol; Life Technologies Inc., Friendsworth, TX). PSF-TFE3 hybrid transcripts were detected using the PSF forward primer 5 0 -TGGTGGTGGCATAGGTTATG-3 0 and the TFE3 reverse primer 5 0 -CGTTTGATGTTGGGCAGCTC-3 0 . NonO (p54nrb)-TFE3 hybrid transcripts were detected using the NonO (p54nrb) forward primer 5 0 -GA-GAAACTAGACACAGCAAC-3 0 and the TFE3 reverse primer 5 0 -CTTTCTTCTGCCGTTCCTTC-3 0 . PRCC-TFE3 hybrid transcripts were detected using the PRCC forward primer 5 0 -CCAAGCCAAAGAAGAGGA-3 0 and the TFE3 reverse primer 5 0 -AGTGTGGTG-GACAGG TACTG-3 0 . CLTC-TFE3 hybrid transcripts were detected using the CLTC forward primer 5 0 -AGTCGCGTTGTT GGAAAGTATTGTG-3 0 and a TFE3 reverse primer 5 0 -CAAAAGGGCCTTTGCCTCGGTC-3 0 . ASPL-TFE3 fusion transcripts were detected using a forward primer from ASPL 5 0 -AAAGAAGTCCAAGTCGGGCCA-3 0 and a TFE3 exon 4 reverse primer 5 0 -CGTTTGATGTTGGG CAGCTCA-3 0 . Normal TFE3 transcripts were detected using the forward primer 5 0 -CCCGCAAGTGC-CCAGC CACTG-3 0 (exon 3) and reverse primer 5 0 -CAGTTCCT TGATCCTGTCG-3 0 (exon 4). b-actin transcripts were detected using the forward primer 5 0 -ATCACCATTGG CAATGAGCG-3 0 and reverse primer 5 0 -TTGAAGG TAGTTTCGTGGAT-3 0 .
RESULTS
We collected 121 consecutive adult RCC cases from 2001 to 2009. The first TMA contained tumor and nonneoplastic adjacent tissue from all 121 cases. TFE3 IHC was applied to the first TMA. There were 6 cases with strong and moderate TFE3 staining and 5 cases with weak TFE3 staining. The second TMA, constructed after the first, included all TFE3-positive (6 strong/moderate and 5 weak) cases and 5 TFE3-negative cases. A dualcolor break-apart FISH assay that detects chromosomal rearrangements at the Xp11.2 region was applied to the second TMA. The 6 cases (Table 1) with strong/moderate TFE3 staining were confirmed as TFE3 translocation RCC by FISH. Cases #1 to #4 have been reported previously. 34 The 5 cases with weak TFE3 staining and 5 cases with negative TFE3 staining did not show chromosomal rearrangement at the Xp11.2 region by FISH. We concluded that the 6 cases with strong/moderate TFE3 staining were TFE3 translocation RCCs. Clinical and pathologic features of these cases are reported below. Among the remaining 115 RCC cases, around 73% of cases were clear cell RCC, 20% of cases were papillary RCC, and the remaining 7% of cases were consistent with chromophobe and unclassified RCC. This reflects that our RCC cases are a representative cross-section of the general population.
Clinical and Histopathologic Features of TFE3 Translocation RCC
Patients with TFE3 translocation RCC were all female with a mean age of 43 years (range, 30 to 65 y). None of the patients had been previously exposed to cytotoxic chemotherapy. The most common presenting symptom was metastatic lesion(s); however, the majority of patients were asymptomatic. Five of the 6 patients had distant and/or lymph node metastasis either synchronously or metachronously. One patient died 5 months after diagnosis. The remaining patients were alive at follow-up, which ranged from 21 to 47 months. The tumors ranged in size from 7.2 to 25 cm (Table 1) . Grossly, the tumors were not distinguishable from other RCC subtypes. They contained tan-yellow necrotic areas, hemorrhage, and cystic degeneration ( Figs. 1A, B ).
On microscopic examination, several of the TFE3 translocation RCC cases had similar morphologies. The tumors were composed of large polygonal cells with discrete borders, granular eosinophilic to clear cytoplasm, vesicular nuclear chromatin, and prominent nucleoli. Cells were arranged in nests and papillary/pseudopapillary structures (Figs. 1C, D). Pigment and hyaline nodules were not seen. A few psammoma bodies were present. Although the tumors resembled clear cell and papillary RCC in that they contained clear cytoplasm and papillary architecture, they did not contain the typical delicate and uniform small vessels typical of clear cell RCC. In addition, collections of foamy histiocytes are rare in Xp11 translocation RCC compared with papillary RCC. Other histologic patterns could be seen. The specimen from patient #1 showed polygonal cells with large cytoplasmic vacuoles and eccentric nuclei (signet ring-like) with a microcystic growth pattern (Figs. 1E, F). The specimen from patient #5 showed a solid/syncytial growth pattern and grade 4 nuclear atypia (Figs. 1G, H).
Xp11 translocation RCC demonstrates a different immunoprofile compared with other RCC subtypes. Although there was slight variation in immunostaining from case to case in our 6 Xp11 translocation RCCs, most cases showed weak and focal staining for renal marker CD10 ( Fig. 1I ) and epithelial marker AE1/3 ( Fig. 1J ) and EMA. The melanocytic markers Melan-A and HMB-45 (Figs. 1K, L) were positive in 3 cases. Xp11 translocation RCC showed variable moderate/weak to negative vimentin staining, in comparison with the strong and diffuse staining typically seen in clear cell RCC. All cases were strongly positive to moderately positive for TFE3 ( Fig. 1M ).
Biological Meaning of Weak TFE3 Nuclear Staining
During our initial screening of TFE3 translocation RCC by TMA and IHC, we found that a small but significant portion of cases (5 cases, approximately 4%) showed weak nuclear staining for TFE3 (Figs. 2C, D). Using a FISH assay, which we developed earlier, 34 we did not find any evidence of chromosomal translocations involving the Xp11 region in any of the 5 cases ( Fig. 2G ). We also performed RT-PCR on one of the cases in which fresh frozen tissue was available. We used primers for wild-type (nontranslocation) and all 5 known translocation types (ASPL-TFE3, PRCC-TFE3, PSF-TFE3, CLTC-TFE3, and Nono-TFE3). Only wild-type (nontranslocation) TFE3 transcript was detected ( Fig. 2E ). b-actin loading controls were detected in each reaction (Fig. 2F ). Taken together, the FISH and RT-PCR results strongly suggest that weak nuclear staining appears to be due to the expression of the full-length TFE3 protein, rather than a chimeric fusion protein resulting from translocation. Similar results were also observed by another group. 3 
Clinical and Histopathologic Features of TFEB Translocation RCC
In our records, there was 1 case of RCC with t(6,11). The patient is an African American male with a renal neoplasm diagnosed incidentally on computed tomographic scan after presenting with abdominal trauma (age 17 y). He was lost to follow-up and returned 3 years later (age 20 y) complaining of abdominal pain. A left total nephrectomy was performed. The tumor measured 19 cm in its greatest dimension. Grossly, the tumor was tan to yellow-brown with diffuse hemorrhage and necrosis. Degenerative cystic areas were seen in the central portion of the tumor.
Microscopic examination of viable tumor showed solid sheets of medium-sized, monomorphic, polygonal epithelioid cells with multiple areas of tubular and papillary (Figs. 3A, C) . The cells contained clear to granular eosinophilic cytoplasm, well-defined cell borders, and small, round nuclei with occasional small nucleoli ( Figs. 3B, D) . Mitoses were rare, and no psammoma bodies or hyaline nodules were present. The tumor was extensively sampled. Clusters of smaller epithelioid cells, a previously described phenomenon in this tumor, 6 were not identified. The tumor also showed a unique immunoprofile consisting of absent staining for pan-cytokeratin (AE1/3) ( Fig. 3E ) and CD10 (Fig. 3F) , strong diffuse strong positivity for Melan-A, and focal positivity for HMB-45 (Fig. 3H) . The TFEB immunohistochemical stain was heterogenous and ranged from moderate to strong nuclear staining at the periphery of the tissue (Fig. 3J ) to weak or completely negative nuclear staining. This pattern may be due to fixation artifacts affecting antibody binding, an occurrence that has been reported previously. 6 We also applied the TFEB immunohistochemical stain to the first TMA, which contained 121 cases of RCC. Positive TFEB staining was not identified. Although the possibility of a falsenegative result arises because of the nature of the TMA and TFEB antibodies, we believe that this possibility is unlikely because of the rare nature of TFEB translocation RCC.
DISCUSSION
RCCs encompass a spectrum of tumors with unique clinical and histopathologic features as well as characteristic cytogenetic aberrations. 28, 29 Cytogenetic analysis has provided a valuable tool in the diagnosis of the various histologic subtypes and has elucidated how their distinctive molecular profiles correlate with different morphologic patterns. Pediatric RCCs, although uncommon, usually show distinctive chromosomal abnormalities most often involving translocations involving TFE3 and TFEB, members of the MiTF family of transcription factors. 12, 15 Although Xp11 translocation RCC is typically considered a pediatric malignancy, its frequency in the adult population remains underestimated. 14 Several reasons could explain this occurrence. One possibility lies in the fact the translocation RCCs usually overlap morphologically or mimic other RCCs (primarily clear cell and papillary RCC). In contrast to pediatric neoplasms, fresh tissue collection for cytogenetics and molecular analysis is not routinely performed in adult translocation RCC, making further diagnostic testing difficult.
Previous cytogenetic and immunohistochemistrybased studies attempting to estimate the frequency of Xp11 translocation RCC have revealed an incidence of about 1% 14 and 1.6%, 25 respectively, among all RCCs examined in these series. Taking the aforementioned into consideration, along with the fact that RCC is more commonly encountered in the adult population, it is possible that the frequency of Xp11 translocation RCCs in adults may outnumber cases in the pediatric group. 31 Interestingly, our study revealed a frequency close to 5%, likely because routine fresh tissue collection for cytogenetic testing and cryopreservation of tumor samples is a common practice at our institution, allowing us to perform in-depth ancillary studies including cytogenetic analysis, RT-PCR, and FISH. This emphasizes that the combination of histopathology along with molecular studies increases the diagnostic accuracy of these tumors. Our case series is relatively small (121 cases). A more accurate frequency of Xp11 translocation RCC needs to be confirmed by larger and multiinstitutional studies. If our results are representative of the general population, there will be approximately 2500 new TFE3 translocation RCC cases each year in the United States, considering NCI estimates of 58,240 new kidney tumor cases in the United States in 2011.
Although prior exposure to chemotherapy remains the only known risk factor for the development of Xp11 translocation RCC, 7 none of the patients in our study had a history of chemotherapy exposure. Female predominance, as described in the literature, 11, 14 was seen in our study. All TFE3 translocation RCC cases were present in female patients with a mean age of 43 years, contrasting with the much younger mean age (B15 y or less) of all 121 RCC patients examined.
Grossly, Xp11 translocation RCCs are large tumors resembling conventional clear cell RCC with a variegated appearance including tan-yellow areas admixed with hemorrhagic and necrotic tissue foci. The mean tumor size in our series was 12.5 cm, almost double of that reported in other series. 11, 14 This may be because of the fact that our hospital serves a population of predominantly low socioeconomic status in which patients tend to seek medical attention at more advanced stages of disease because of limited access to health care.
As described by Argani and Ladanyi, TFE3 gene fusions translate histologically to a distinct morphologic pattern consisting mainly of mixed papillary and nested cells with granular eosinophilic cytoplasm. 1, 6 The majority of our cases were consistent with this histologic picture. Intriguingly, we also found some unique histologic features that have not been previously described in the literature. These include signet ring-like cells in a microcystic arrangement (Figs. 1E, F) with high-grade cytologic atypia and nonclear cells laid in solid/syncytial architectural patterns (Figs. 1G, H). Similar morphology of high-grade cytologic atypia and nonclear cells has been reported previously in Xp11 RCC. 9 Abundant psammoma bodies and hyaline nodules were not seen in our cases. These tumors did not contain the typical delicate and uniform small vessels common in clear cell RCC or collections of foamy histiocytes common in papillary RCC. Xp11 translocation RCC should also be distinguished from clear cell papillary RCC, 23 a newly described entity. Most clear cell papillary RCCs contain both clear cell and papillary features in a style similar to that of Xp11 translocation RCCs. A cardinal feature that differentiates these tumors is the location of the nuclei toward either the middle or upper pole of the cell. 23 This reverse polarity is a feature not seen in Xp11 translocation RCC.
Xp11 translocation RCCs are known to variably express epithelial immunohistochemical markers and are consistently positive for RCC marker antigens and CD10. 5, 11, 14 Nevertheless, nuclear immunoreactivity to TFE3 protein remains the most sensitive, specific, and distinct immunohistochemical marker for these neoplasms. 5, 11, 14 For a comprehensive immunohistochemical profile of these tumors, please see a recent publication. 5 The TFE3 protein antibody recognizes the C-terminal portion of TFE3. The C-terminal portion is retained in the gene fusion. 9 Its overexpression in TFE3 translocation RCC is believed to be due to the upregulation of a chimeric TFE3 protein resulting from a swap to a stronger promoter. 9 In our study, 6 cases expressed moderate to strong nuclear staining, whereas 5 cases exhibited weak TFE3 staining. Further investigation of the latter cases by FISH and/or RT-PCR failed to reveal any evidence of TFE3 rearrangement, suggesting that the weak nuclear TFE3 staining may be the result of an upregulation of the full-length TFE3 protein, translating into a weak expression. 3 This upregulation is in contrast to the chimeric fusion proteins resulting from Xp11.2 gene rearrangements. These results reconfirm that weak nuclear staining should not be interpreted as true-positive staining in these tumors and that TFE3 IHC is a sensitive marker for Xp11 translocation RCC. 9 In addition, in all 6 Xp11 translocation RCC cases determined by FISH and/or cytogenetics, RT-PCR showed strong to moderate nuclear TFE3 staining. These findings also showed that, with careful evaluation, TFE3 IHC can be a specific marker for these tumors as well. 9 The diagnosis of Xp11 translocation RCC requires the integration of clinical information, histopathologic features, TFE3 IHC stain, and cytogenetic and molecular studies. Any of the following scenarios should prompt research to further investigate the possibility of an Xp11 translocation RCC: young/middle-aged patient (< 45 y) with metastatic RCC; typical clear cell with papillary histopathologic features along with minimal immunohistochemical reactivity to cytokeratins and EMA. TFE3 IHC is a sensitive and relatively specific marker for Xp11 translocation RCC that could be used as a screening method, followed by FISH assay, which should be reserved as a helpful ancillary technique in those cases with equivocal TFE3 IHC staining. To date, the diagnosis of Xp11 translocation RCC remains largely an academic exercise because of the lack of a specific therapy for these neoplasms. However, awareness among pathologists is pivotal in order to arrive at an accurate diagnosis.
Xp11 translocations have been implicated in several tumors other than RCC. Alveolar soft part sarcoma (ASPS) with the ASPL-TFE3 gene fusion is one example. 26 Interestingly, Xp11 translocation RCCs with identical gene rearrangements have shown histopathologic patterns similar to those of ASPS. 6 Perivascular epithelioid cell tumors (PEComas) have also shown immunoreactivity for TFE3. Folpe et al 21 showed TFE3 positivity in 5 of 17 PEComas. Two cases of PEComa with a PSF-TFE3 gene fusion demonstrated by FISH and RT-PCR have also been reported. 16, 33 More recently, Argani et al 3 reported a subset of lesions currently classified as PEComas that harbor TFE3 gene fusions. He also reported a distinctive type of renal cancer with overlapping features of PEComa, Xp11 translocation carcinoma, and melanoma. 4 In the present series we also report on TFEB t(6;11)(p21;q12) translocation RCC, another rare subtype of RCC. These carcinomas are characterized by fusion of the intronless Alpha gene (11q12) with the first intron of the TFEB transcription factor gene (6p21). 8, 19 TFEB translocation RCCs share similar histopathologic features with TFE3 translocation RCCs but at the same time reveal distinct clinicopathologic features. 6 Microscopically, these tumors display a dimorphic pattern composed of large polygonal epithelioid cells with clear to eosinophilic cytoplasm in a nested pattern comingled with a population of smaller epithelioid-like cells typically clustered around hyaline nodules. 6 In our case, however, this dimorphic pattern was not present. Instead, the tumor was composed of medium-sized polygonal cells with small round nuclei distributed in solid sheets with multiple foci of papillary and tubular architectural patterns, a feature that has been observed in other TFEB translocation RCCs confirmed by cytogenetic studies (P. Argani, personal communication). Immunoprofiling on this case revealed the distinctive features of this tumor subtype, including entirely absent staining for pan-cytokeratins AE1/3 and kidney tubule marker CD10 and a diffuse strong immunoreactivity with HMB-45. TFEB staining showed moderate to strong nuclear staining, which was more prominent at the periphery of the tumor perhaps because of better antigen preservation from more complete fixation at the periphery of the tissue. 6 MITF, an MIT family protein that also includes TFE3, TFEB, and TFEC, has also been implicated in various cancers. MiTF amplification 22 and somatic mutations 18 have been reported in human melanoma. Another correlation of MITF with tumorigenesis has been made for clear cell sarcoma (CCS), 20 a rare sarcoma that expresses melanocytic markers and harbors the EWS-ATF1 chromosomal translocation. The resulting fusion protein occupies the MITF promoter and induces its expression, mediating CCS survival. CCS cells cannot survive in the absence of MITF, although their survival can be rescued by either MITF or the closely related family members TFE3 or TFEB. Reciprocally, UOK109, an Xp11 translocation RCC cell that harbors the NONO-TFE3 translocation, could not survive upon TFE3 knockdown by small interference RNA but were rescued by expression of MITF. 20 These elegant experiments demonstrated functional oncogenic overlap among MITF, TFE3, and TFEB. On the basis of oncogenic gene fusion-translocation events, dysregulation of MITFrelated family members, and genetic evidence of functional redundancy among several of these factors, Fisher and colleagues suggested a reevaluation of the classification of these tumors. 27 They coined the term "MiT family cancers," which include a subset of melanoma, TFE3 and TFEB translocation RCC, ASPS, and CCS. 27 This observation is of crucial importance, as recent therapeutic strategies focusing on targeting common molecular pathways that contribute to critical steps in malignant transformation have proven successful. One such example is with the tyrosine kinase inhibitor Imatinib, which targets BCR-ABL and c-KIT and significantly improves the prognosis of chronic myeloid leukemia and gastrointestinal stromal tumors, respectively. Even though the MiT family of cancers differs in many clinical aspects, these cancers share common or closely related oncogenic factors. It is reasonable to predict that targeted therapies for the MITF family of proteins will be effective for all members of the Mit family of cancers including TFE3 translocation RCC.
In conclusion, this study reports on the unique clinicopathologic features of adult RTCs using TMA, immunohistochemistry, cytogenetics, and FISH. In addition to histologic diagnosis, these adjunctive techniques could potentially be used in an algorithmic combination to strengthen diagnostic accuracy and greatly increase the chances of therapeutic success. We found that these tumors are not uncommon in light of a single-institution experience. Despite the significant advances and recent progress in the understanding of the molecular basis of translocation-associated RCCs, many aspects of these tumors remain to be uncovered.
